Clinical trials: Lung Cancer Non-small Cell Stage IV
Non-Small Cell Lung Cancer (NSCLC, Locally Advanced or Metastatic, Second-line
This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.
The purpose of this study is to assess the efficacy and safety of ZD6474 in patients with NSCLC after Failure of Prior Platinum-based Chemotherapy.
- Trial name
- NCT00047840
- Testing
- ZD6474, Docetaxel
- Where
- 26 sites in United States, Czechia and 1 more
- Volunteers
- 129 people
- Sponsor
- Genzyme, a Sanofi Company
NSCLC
Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion
This is a Phase 2, Multicenter, Open-Label Study to Assess the Efficacy and Safety of Furmonertinib in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR)…
- Trial name
- NCT05466149
- Testing
- Furmonertinib
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Allist Pharmaceuticals, Inc.
Non-Squamous Non-Small Cell Lung Cancer (NSCLC), Advanced Non Squamous NSCLC
A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients
The goal of this clinical trial is to learn how roginolisib works in combination with dostarlimab with or without docetaxel in adult patients with advanced non small-cell lung cancer.
- Trial name
- PULMO-01 (NCT06879717)
- Testing
- roginolisib, Dostarlimab, Docetaxel
- Where
- 7 sites in Belgium, Italy and 1 more
- Volunteers
- 45 people
- Sponsor
- iOnctura
Non-small Cell Lung Cancer
A Study of BL-B01D1 Combined With Glecirasib in Patients With KRAS G12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This Phase II study is a clinical study to explore the efficacy and safety of BL-B01D1 for injection in combination with glecirasib in the treatment of patients with locally advanced or metastatic non-small cell lung cancer with…
- Trial name
- NCT07827261
- Testing
- BL-B01D1, Glecirasib
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-Small Cell Lung Cancer With EGFR Mutation
A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib
This is an open-label phase 2 study to evaluate the safety, tolerability and preliminary anti-tumour activity of ABSK043 in combination with Firmonertinib in patients with Epidermal Growth Factor Receptor-mutated (EGFRm+) locally…
- Trial name
- NCT06668103
- Testing
- ABSK043 in combination with Firmonertinib
- Where
- 5 sites in China
- Volunteers
- 54 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Non-small Cell Lung Cancer
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
This study was designed to determine the safety and tolerability of PB101 (autologous NK cell product) in combination with standard of care EGFR-TKI in patients with EGFR-mutated advanced non-small cell lung cancer.
- Trial name
- NCT07271446
- Testing
- PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Precision Biotech Taiwan Corp.
Locally Advanced or Metastatic NSCL Cancer Stage IIIB IV
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
This is a Phase I, open label multicentre study of selumetinib administered orally in combination with first line chemotherapy regimens to patients with advanced/metastatic NSCLC.
- Trial name
- SELECT-3 (NCT01809210)
- Testing
- selumetinib, gemcitabine, cisplatin
- Where
- 4 sites in United Kingdom
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer
A Study of SI-B001+SI-B003± Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phase Ib: To observe the safety and tolerability of the combination of SI-B001 and SI-B003, and to determine the recommended dose of phase II clinical study (RP2D) in the indication of locally advanced or metastatic non-small…
- Trial name
- NCT05949606
- Testing
- SI-B001, SI-B003
- Where
- China
- Volunteers
- 95 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Non-small Cell Lung Cancer
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve…
- Trial name
- NCT07183189
- Testing
- SHR-A2009 ; Aumolertinib, Aumolertinib
- Where
- China
- Volunteers
- 582 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Metastatic Non-Small Cell Lung Cancer
Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
The purpose of this study is to evaluate progression-free survival among subjects with KRAS mutation positive Non-Small Cell Lung Cancer (NSCLC) treated with erlotinib plus tivantinib (ARQ 197) compared to single agent…
- Trial name
- NCT01395758
- Testing
- ARQ 197 plus erlotinib, Pemetrexed, docetaxel or gemcitabine
- Where
- 13 sites in United States
- Volunteers
- 96 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Non-small Cell Lung Cancer
Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative
This is a phase Ib, multi-center, open label study evaluating the safety and efficacy of CT053PTSA in combination with gefitinib in patients with EGFR mutation, T790M negative NSCLC who have progressed after EGFR TKI treatment.
- Trial name
- NCT03758287
- Testing
- CT053PTSA, Gefitinib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Non-small Cell Lung Cancer (NSCLC)
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small…
- Trial name
- NCT06448793
- Testing
- Approved Non-small Cell Lung Cancer (NSCLC) therapies
- Where
- United Kingdom
- Volunteers
- 650 people
- Sponsor
- Bristol-Myers Squibb
Lung Cancer
Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer
The purpose of this study was to evaluate the efficacy and safety of the combination of nivolumab plus epacadostat in combination with platinum chemotherapy compared with platinum chemotherapy alone, in participants with…
- Trial name
- NCT03348904
- Testing
- Nivolumab, Epacadostat, Carboplatin
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- Incyte Corporation
Lung Cancer, Chemotherapy-Induced Thrombocytopenia
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to identify an effective, well tolerated dose and schedule of romiplostim that is appropriate for the treatment of chemotherapy induced thrombocytopenia (CIT) in patients with non-small cell lung…
- Conditions
- Lung Cancer, Chemotherapy-Induced Thrombocytopenia, Non-Small Cell Lung Cancer, Cancer
- Trial name
- NCT00413283
- Testing
- Romiplostim, Gemcitabine, Carboplatin
- Where
- 113 sites in United States, Austria and 6 more
- Volunteers
- 63 people
- Sponsor
- Amgen
Non-Small Cell Lung Cancer
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
This is a global, multicenter, open-label study that aims to assess the efficacy and safety of zelenectide pevedotin in participants with previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer…
- Trial name
- NCT06933329
- Testing
- Zelenectide pevedotin
- Where
- 3 sites in France, Spain
- Volunteers
- 73 people
- Sponsor
- BicycleTx Limited
Lung Neoplasms
GILT Docetaxel - Non-Small Cell Lung Cancer
Primary Objective: To compare response rate between genotypic groups and control group. Secondary Objective: To determine the safety, time to treatment failure and survival in control and genotypic arms.
- Trial name
- NCT00174629
- Testing
- Docetaxel/DDP, docetaxel/gemcitabine
- Where
- 3 sites in Germany, Spain and 1 more
- Volunteers
- 449 people
- Sponsor
- Sanofi
NSCLC
Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer
The Phase 2 study described in this protocol will serve to evaluate the antitumor activity, safety and pharmacokinetic profile of Imprime PGG when combined with cetuximab and concomitant paclitaxel and carboplatin therapy in…
- Trial name
- NCT00874848
- Testing
- Imprime PGG Injection, Cetuximab, Paclitaxel
- Where
- 14 sites in United States, Germany
- Volunteers
- 90 people
- Sponsor
- HiberCell, Inc.
Lung Cancer
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T138067 in treating patients who have locally advanced…
- Trial name
- NCT00022243
- Testing
- batabulin sodium
- Where
- 2 sites in United States
- Sponsor
- Tularik
Non Small Cell Lung Cancer
Dosage Schedule Study of Pemetrexed Monochemotherapy for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Patients affected by non-small cell lung cancer (NSCLC) will be treated in pemetrexed monochemotherapy regimen for a maximum of 8 cycles.
- Trial name
- NCT00370292
- Testing
- Pemetrexed - Before Protocol Amendment, Pemetrexed - After Protocol Amendment
- Where
- Italy
- Volunteers
- 19 people
- Sponsor
- Eli Lilly and Company
Lung Cancer
Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer
The purpose of this study is to determine the safety and the maximum tolerated dose (MTD) of GRN163L when administered in combination with a standard paclitaxel/carboplatin regimen to patients with advanced or metastatic…
- Trial name
- NCT00510445
- Testing
- Imetelstat Sodium (GRN163L)
- Where
- 4 sites in United States
- Volunteers
- 27 people
- Sponsor
- Geron Corporation